|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 455.48 USD | -0.41% |
|
+5.04% | +13.11% |
| 05:31pm | Vertex's gene therapy shows promise in younger children with blood disorders | RE |
| 06/12 | Vertex Pharmaceuticals Insider Sold Shares Worth $2,024,955, According to a Recent SEC Filing | MT |
| Capitalization | 12TCr 9.93TCr 9.31TCr 8.67TCr 16TCr 10,40100Cr 17TCr 1,08800Cr 42TCr 4,91200Cr 43TCr 42TCr 17,96100Cr | P/E ratio 2025 * |
29.3x | P/E ratio 2026 * | 26x |
|---|---|---|---|---|---|
| Enterprise value | 11TCr 9.16TCr 8.58TCr 8TCr 15TCr 9,58700Cr 16TCr 1,00300Cr 39TCr 4,52800Cr 40TCr 39TCr 16,55600Cr | EV / Sales 2025 * |
8.88x | EV / Sales 2026 * | 7.8x |
| Free-Float |
99.04% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -0.41% | ||
| 1 week | +5.04% | ||
| Current month | +5.04% | ||
| 1 month | +9.23% | ||
| 3 months | +14.99% | ||
| 6 months | +2.63% | ||
| Current year | +13.11% |
| 1 week | 423.46 |  | 463.85 |
| 1 month | 406.67 | | 463.85 |
| Current year | 362.5 | | 519.68 |
| 1 year | 362.5 | | 519.68 |
| 3 years | 282.21 | | 519.88 |
| 5 years | 176.36 | | 519.88 |
| 10 years | 71.46 | | 519.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Agam Upadhyay
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 65 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 69 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 56 | 18/06/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.41% | +5.04% | -0.97% | +43.41% | 12TCr | |
| -0.41% | -6.06% | +22.37% | +173.58% | 90TCr | |
| -0.27% | -2.41% | +35.05% | +12.95% | 49TCr | |
| -1.15% | -0.71% | +28.33% | +37.90% | 40TCr | |
| +0.26% | +1.14% | +21.30% | +0.44% | 33TCr | |
| +0.58% | -2.73% | +28.01% | +20.71% | 28TCr | |
| +0.19% | +2.49% | +18.48% | +24.80% | 26TCr | |
| -1.16% | -4.87% | -3.70% | -9.35% | 25TCr | |
| +1.24% | -2.33% | -59.84% | -31.25% | 21TCr | |
| -3.02% | -4.51% | +20.25% | +15.79% | 18TCr | |
| Average | -0.22% | -1.49% | +10.93% | +28.90% | 34.12TCr | |
| Weighted average by Cap. | -0.10% | -2.53% | +16.99% | +55.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.2TCr 1.03TCr 965.75Cr 900.15Cr 1.66TCr 1,07900Cr 1.81TCr 11TCr 4.36TCr 51TCr 4.5TCr 4.41TCr 1,86400Cr | 1.3TCr 1.12TCr 1.05TCr 979.3Cr 1.81TCr 1,17400Cr 1.97TCr 12TCr 4.75TCr 55TCr 4.9TCr 4.79TCr 2,02800Cr |
| Net income | 397.96Cr 342.09Cr 320.46Cr 298.69Cr 551.7Cr 36TCr 600.09Cr 3.75TCr 1.45TCr 17TCr 1.49TCr 1.46TCr 62TCr | 448.81Cr 385.79Cr 361.41Cr 336.86Cr 622.18Cr 40TCr 676.75Cr 4.23TCr 1.63TCr 19TCr 1.68TCr 1.65TCr 70TCr |
| Net Debt | -904.05Cr -777.12Cr -727.99Cr -678.54Cr -1.25TCr -81TCr -1.36TCr -8.52TCr -3.29TCr -38TCr -3.39TCr -3.32TCr -1,40500Cr | -1.38TCr -1.19TCr -1.12TCr -1.04TCr -1.92TCr -1,24600Cr -2.09TCr -13TCr -5.04TCr -59TCr -5.2TCr -5.09TCr -2,15200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/25/05 | 455.48 $ | -0.41% | 9,11,424 |
| 04/25/04 | 457.36 $ | -1.25% | 15,18,932 |
| 03/25/03 | 463.13 $ | +6.92% | 25,42,611 |
| 02/25/02 | 433.15 $ | +1.77% | 13,99,828 |
| 01/25/01 | 425.60 $ | -1.85% | 11,74,298 |
Delayed Quote Nasdaq, December 06, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition